United States Patent and Trademark Office

Ocean Biomedical (NASDAQ: OCEA) Announces New Patent for Anti-Fibrosis Discovery with Allowance in Alcoholic Liver Disease and Multiple Fibrotic Conditions, Leading Causes of Death in the U.S.

Retrieved on: 
Tuesday, August 29, 2023
Patent, Human, Ocean Biomedical, NASH, RI, United States Patent and Trademark Office, Lupus, Asbestosis, Pulmonary fibrosis, Fibrosis, HPS, EPA, Connective tissue, Silicosis, Hermansky–Pudlak syndrome, Fatty liver disease, IPF, Alcoholic liver disease, Idiopathic pulmonary fibrosis, Rheumatoid arthritis, Scleroderma, Pharmaceutical industry, MD

Providence, RI, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA) announced today that the United States Patent and Trademark Office has issued a patent covering Ocean’s anti-Chitinase 1 small molecule candidate.

Key Points: 
  • Patent granted for use in IPF, HPS, alcoholic liver disease, nonalcoholic steatohepatitis (NASH), and scleroderma.
  • Providence, RI, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA ) announced today that the United States Patent and Trademark Office has issued a patent covering Ocean’s anti-Chitinase 1 small molecule candidate.
  • Targeted diseases include alcoholic liver disease, idiopathic pulmonary fibrosis (IPF), scleroderma, nonalcoholic steatohepatitis (NASH), and Hermansky-Pudlak Syndrome (HPS), a rare disease that currently has no known treatments.
  • Ocean’s approach has shown an 85%–90% reduction in collagen accumulation in four different IPF and HPS pulmonary fibrosis animal models.

Orexo secures patent protection in the US for OX640, a nasal epinephrine powder product

Retrieved on: 
Tuesday, August 29, 2023
United States Patent and Trademark Office, Patent, ORX, Allergy, Emergency, Patient, Pharmaceutical industry, Orexo

), (STO: ORX) (OTCQX: ORXOY) today announces that the United States Patent and Trademark Office (USPTO) has granted the first US patent specifically related to OX640, Orexo's nasal epinephrine powder product based on the amorphOX® drug delivery platform.

Key Points: 
  • ), (STO: ORX) (OTCQX: ORXOY) today announces that the United States Patent and Trademark Office (USPTO) has granted the first US patent specifically related to OX640, Orexo's nasal epinephrine powder product based on the amorphOX® drug delivery platform.
  • Orexo continues to strengthen its patent portfolio and the new patent, No.
  • US 11,737,980, provides protection for the OX640 product in the US until May 2041.
  • Last year, a European patent was granted, and multiple patent applications have been filed by Orexo protecting OX640 on a global basis until 2044.

Orexo secures patent protection in the US for OX640, a nasal epinephrine powder product

Retrieved on: 
Tuesday, August 29, 2023
United States Patent and Trademark Office, Patent, ORX, Allergy, Emergency, Patient, Pharmaceutical industry, Orexo

), (STO: ORX) (OTCQX: ORXOY) today announces that the United States Patent and Trademark Office (USPTO) has granted the first US patent specifically related to OX640, Orexo's nasal epinephrine powder product based on the amorphOX® drug delivery platform.

Key Points: 
  • ), (STO: ORX) (OTCQX: ORXOY) today announces that the United States Patent and Trademark Office (USPTO) has granted the first US patent specifically related to OX640, Orexo's nasal epinephrine powder product based on the amorphOX® drug delivery platform.
  • Orexo continues to strengthen its patent portfolio and the new patent, No.
  • US 11,737,980, provides protection for the OX640 product in the US until May 2041.
  • Last year, a European patent was granted, and multiple patent applications have been filed by Orexo protecting OX640 on a global basis until 2044.

Enveric Biosciences Strengthens Intellectual Property Portfolio with New U.S. Patent for Tryptamine-derived Prodrugs

Retrieved on: 
Monday, August 28, 2023
Research, Mental Health, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Psilocybin, Patent, Intellectual property, 1836 U.S. Patent Office fire, DMT, Tryptamine, Depression, Therapy, Anxiety, United States Patent and Trademark Office, IP, Prodrug, DSM-IV codes, Addiction, Anxiety disorder, NCE, Growth, Safety, Pharmaceutical industry, Enver Pasha

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced that the United States Patent and Trademark Office issued U.S. Patent No.

Key Points: 
  • Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced that the United States Patent and Trademark Office issued U.S. Patent No.
  • 11,707,441, titled “C4-Carbonothioate-substituted Tryptamine Derivatives and Methods of Using,” pertaining to the Company’s lead candidate EB-373, a psilocin prodrug being developed for the treatment of anxiety disorder.
  • This new patent, issued July 25, 2023, provides Enveric with intellectual property rights for compositions and methods for tryptamine-derived prodrugs utilizing C4-substituted tryptamine derivatives and C4-carbonothiate-substituted tryptamine derivatives.
  • Enveric’s lead product candidate, EB-373, is a new chemical entity (NCE) psilocin prodrug being developed for the treatment of anxiety disorder.

Sparta Biomedical Celebrates Prestigious Recognition in MedTech and Significant Milestone

Retrieved on: 
Thursday, August 24, 2023
Patent, Osteoarthritis, Weight-bearing, Elective surgery, United States Patent and Trademark Office, Von Ormy, Texas, Patient, Sport, Jogging, Medtech, Medical device

MORRISVILLE, N.C., Aug. 24, 2023 /PRNewswire/ -- Sparta Biomedical Inc, a pioneering medical technology company specializing in redefining osteoarthritis treatment, proudly reflects on a momentous period marked by significant recognition and notable achievements.

Key Points: 
  • MORRISVILLE, N.C., Aug. 24, 2023 /PRNewswire/ -- Sparta Biomedical Inc, a pioneering medical technology company specializing in redefining osteoarthritis treatment, proudly reflects on a momentous period marked by significant recognition and notable achievements.
  • MedTech Innovator, a distinguished nonprofit accelerator and competition platform within the healthcare industry, identified Sparta Biomedical as an exceptional innovator in the realm of orthopedics.
  • Reflecting on this achievement, CEO Dushyanth Surakanti stated, "We were honored that Sparta was chosen for the 2023 MedTech Innovator cohort.
  • This recognition underscores our dedication to developing innovative solutions that empower patients to regain mobility and lead lives of fulfillment."

GBT IP Portfolio Segmental Update:

Retrieved on: 
Friday, August 18, 2023
Graphics processing unit, DFM, Patent, Intellectual property, Analog, CIP, Photon, Telecommunications, United States Patent and Trademark Office, 3D, IC, Design, Light, Photonics, Research, ICS, IP, IEEE Photonics Technology Letters, Publishing, Nature, Machine learning, SAN, Electro, OTC, Artificial intelligence, MP, GBT, Architecture, PIC, Silicon, Programmable interrupt controller, RF, Television, 3D printing, Printed circuit board

GBT received a notice of allowance for its predictive technology for designing and manufacturing three-dimensional, multi-planar semiconductors patent.

Key Points: 
  • GBT received a notice of allowance for its predictive technology for designing and manufacturing three-dimensional, multi-planar semiconductors patent.
  • SAN DIEGO, Aug. 18, 2023 (GLOBE NEWSWIRE) -- GBT Technologies Inc. ( OTC PINK: GTCH ) ("GBT” or the “Company”), together with GBT Tokenize Corp., its 50% subsidiary and owner of GBT’s intellectual property portfolio, provides a segmental intellectual property portfolio update as related to its patents filed to date.
  • Although the patent has already received a notice of allowance, GBT is interested in further protecting its intellectual property (IP) rights by overcoming any potential prior art and securing important claims.
  • The Company plans to expand its 3D, multi-planar semiconductor architecture IP next year and file additional patent applications in this domain.

60 Degrees Pharmaceuticals Registers ACLR8-LR, a Phase IIB Study of Tafenoquine for Treatment of COVID-19, on ClinicalTrials.gov

Retrieved on: 
Tuesday, August 15, 2023
Patent, IIB, Therapy, Marketing, Public, United States Patent and Trademark Office, COVID-19, Urinary tract infection, Malaria, Infection, COVID, Risk, ClinicalTrials.gov, Degree, HIV disease progression rates, Patient, Standard of care, Public health, Ageing, FDA, IND, Disease, Tafenoquine, Pharmaceutical industry

The trial will be conducted by 60P’s majority-owned subsidiary, 60P Australia Pty Ltd, which opened a new IND on August 14, 2023.

Key Points: 
  • The trial will be conducted by 60P’s majority-owned subsidiary, 60P Australia Pty Ltd, which opened a new IND on August 14, 2023.
  • “Publicly registering ACLR8-LR represents an important milestone in 60P’s clinical research strategy,” said Chief Executive Officer of 60 Degrees Pharmaceuticals, Geoffrey Dow.
  • In April, the United States Patent and Trademark Office (USPTO) issued a patent covering the use of tafenoquine as a treatment for COVID-19 disease.
  • 60P now owns the exclusive rights for the use of tafenoquine for treatment of lung infections including COVID-19 in the U.S. through 2040.

LIS Technologies Inc. Acquires 100% of CRISLA Inc., a USA Company That Holds a Patented Advanced Laser Enrichment Technology Viable for the Domestic Production of High-Assay Low Enriched Uranium (HALEU)

Retrieved on: 
Monday, August 14, 2023
Uranium, WPAFB, Atomic Energy Act of 1946, II, Congress, CO, Inflation, Acquisition, Patent, HEU, Berkeley, R, United States Patent and Trademark Office, Isotope, Nuclear engineering, GLE, University, MS, HALEU, Molecular laser isotope separation, VII, LIS, EUV, Entrepreneurship, Stellenbosch University, Intellectual property, Laser, USAF, Nuclear fuel, Eye, Nuclear energy, Physics, United States Congress, United, Void coefficient, UO2, SF6, LEU, DOE, Extreme ultraviolet, Laser isotope separation, Architecture, UF6, Inflation Reduction Act of 2022, MLIS, FTD, CO2, U3O8, Extracted, European Parliament Liaison Office with the US Congress, Rare-earth element, Uranium mining

A registered nuclear engineer in the State of California, he explored Molecular Laser Isotope Separation (MLIS) of gaseous UF6 and hexafluorides MoF6 and SF6.

Key Points: 
  • A registered nuclear engineer in the State of California, he explored Molecular Laser Isotope Separation (MLIS) of gaseous UF6 and hexafluorides MoF6 and SF6.
  • He has hands-on experience with nuclear reactors, uranium enrichment, nuclear rockets, and space satellite engineering.
  • He is an accomplished professional with 35 years of diverse technical & management experience in advanced laser & optical systems and applications.
  • Furthermore, the US Congress, through the Inflation Reduction Act, provided $700 million to support the development of a domestic supply chain for high-assay low-enriched uranium.

Lantern Pharma Receives Notice of US Patent Allowance for Drug Candidate LP-184 for the Treatment of Rare Pediatric Brain Cancer, ATRT

Retrieved on: 
Monday, August 14, 2023
Oncology, Health, Technology, Artificial Intelligence, Pharmaceutical, Biotechnology, Pancreatic cancer, Patent, DNA, ATRT, Radiation, Brain, Central nervous system, GBM, ODD, United States Patent and Trademark Office, Parent, Cancer, ML, DRS, Research, Atypical teratoid rhabdoid tumor, CNS, Glioblastoma, Patient, Machine learning, Child, Glioma, Artificial intelligence, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Safety, Nursing, Pharmaceutical industry, Lantern

“Historically, pediatric ATRT has been treated with a combination of surgery, radiation, and chemotherapy, but unfortunately, these approaches have often resulted in unfavorable long-term outcomes for the children affected.”

Key Points: 
  • “Historically, pediatric ATRT has been treated with a combination of surgery, radiation, and chemotherapy, but unfortunately, these approaches have often resulted in unfavorable long-term outcomes for the children affected.”
    Drs.
  • Lantern has rapidly advanced the clinical development of LP-184, activated the initial clinical trial sites, and has begun screening patients.
  • The U.S. Food and Drug Administration (FDA) has previously granted LP-184 Rare Pediatric Disease Designation and Orphan Drug Designation (ODD) for the treatment of pediatric patients with ATRT.
  • The FDA has also previously granted LP-184 ODD for the treatment of pancreatic cancer and for the treatment of malignant glioma, including GBM.

Cerebro Capital Announces Patent Issued for Artificial Intelligence Derived Anonymous Marketplace

Retrieved on: 
Wednesday, August 16, 2023
United States Patent and Trademark Office, Patent, Algorithm, Cerebro, Bank

BALTIMORE, Aug. 16, 2023 /PRNewswire/ -- Cerebro Capital , a leading fintech company specializing in democratizing access to debt capital for medium sized businesses, is pleased to announce that a patent for its groundbreaking AI Derived Anonymous Marketplace has been issued.

Key Points: 
  • BALTIMORE, Aug. 16, 2023 /PRNewswire/ -- Cerebro Capital , a leading fintech company specializing in democratizing access to debt capital for medium sized businesses, is pleased to announce that a patent for its groundbreaking AI Derived Anonymous Marketplace has been issued.
  • The patent, a culmination of a four year rigorous process with the United States Patent and Trademark Office, represents a significant milestone for the company.
  • The approved patent safeguards the innovative algorithms and cutting-edge processes powering Cerebro's online platform.
  • Notably, the platform empowers borrowers to maintain complete anonymity until they are ready to proceed with closing a new transaction.